GLUEMonte Rosa Therapeutics, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $124M
- 64% YoY
- Operating margin
- -43.8%
- 59% YoY
- EBITDA
- −$46M
- 37% YoY
- Market cap
- $917M
- Employees
- 150
- $824K revenue each
- Net debt / EBITDA
- —
- AI in 10-K
- 4.0
- mentions per 10K words
Takeover score 3 of 13
Fixable underperformance 2 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCYes15% of revenueOver 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentYes79% lowest supportAny vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeNo$824K · 67th pctBottom quartile of its SIC industry
- Quiet on AINo4.0 per 10K words · 78th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$917M market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$4M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $76M | $124M | 64% |
| Operating income | −$73M | −$112M | −$143M | −$81M | −$54M | 33% |
| Net income | −$74M | −$109M | −$135M | −$73M | −$39M | 47% |
| Operating cash flow | −$59M | −$92M | −$44M | $42M | −$23M | 154% |
| Capex | $10M | $13M | $19M | $4M | $5M | 18% |
| Stock-based comp | $5M | $12M | $17M | $18M | $19M | 4.1% |
| Dividends | $0 | $0 | $0 | $0 | $0 |
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| Jul 6, 2026 | New Enterprise Associates 17, L.P. | SCHEDULE 13D/A | 7.9% | Passive |
| Mar 19, 2026 | New Enterprise Associates 17, L.P. | SCHEDULE 13D/A | 19.2% | Passive |
| Jan 9, 2026 | Versant Venture Capital VI, L.P. | SCHEDULE 13D/A | 5.0% | Passive |
| Nov 12, 2025 | Versant Venture Capital VI, L.P. | SCHEDULE 13D/A | 5.1% | Passive |
| Oct 30, 2024 | Versant Venture Capital VI, L.P. | SC 13D/A | 6.6% | Passive |
| Sep 24, 2024 | Versant Venture Capital VI, L.P. | SC 13D/A | 8.3% | Passive |
| Aug 12, 2024 | New Enterprise Associates 17, L.P. | SC 13D/A | 12.5% | Passive |
| Aug 12, 2024 | Versant Venture Capital VI, L.P. | SC 13D/A | 11.1% | Passive |
| May 13, 2024 | New Enterprise Associates 17, L.P. | SC 13D/A | 15.2% | Passive |
| Nov 9, 2023 | Versant Venture Capital VI, L.P. | SC 13D/A | 13.7% | Passive |
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $4M · 37
- Net
- −$4M
Pay vs performance
No pay-versus-performance disclosure yet.